Systemic Therapy in Soft Tissue Sarcomas: Past, Present and Future

Indian Journal of Surgical Oncology

Volumn 2, Issue 4, 2011, Pages 327-331

  Purohit, Samit ^a   Bhise, Rohan ^a   Appachu, Sandhya ^a   Lakshmaiah, K C ^a   Govindbabu, K ^a  

^a KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

Adjuvant chemotherapy; Soft tissue sarcoma; Trabectedin

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EVEROLIMUS; GAMMA INTERFERON; IFOSFAMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELPHALAN; MESNA; PAZOPANIB; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TRABECTEDIN; TUMOR NECROSIS FACTOR ALPHA;

ALOPECIA; ANGIOSARCOMA; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOSENSITIVITY; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTHERMIC THERAPY; HYPERTRANSAMINASEMIA; LEIOMYOSARCOMA; LIPOSARCOMA; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; SURVIVAL TIME; SYNOVIAL SARCOMA; THROMBOCYTOPENIA;

EID: 84873250219     PISSN: 09757651     EISSN: 09766952     Source Type: Journal    
DOI: 10.1007/s13193-012-0140-8     Document Type: Review

References (22)

1. Benjamin R, Pisters Peter WT, Helman LJ, Bramwell Vivien HC, Rubin BP, O'Sullivan B (2008) Sarcomas of soft tissue. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKeena WG (eds) Clinical oncology, 4th edn. Churchill Livingstone Elsevier, Philadelphia, pp 2009-2056.
2. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R et al (1995) Doxorubicin versus CyVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13: 1537-1545.
3. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG et al (2007) Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 25: 3144-3150.
4. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M, Members of the Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care (2008) Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev 34: 339-347.
5. Sauer R, Schuchardt U, Hohenberger W, Wittekind C, Papadopoulos T, Grabenbauer GG et al (1999) Neoadjuvant radiochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control. Strahlenther Onkol 175: 259-266.
6. Goryzak E, Azzarelli A, Buesa J, Bramwell VH, van Coevorden F, van Geel AN et al (2001) A randomized Phase II study on neoadjuvant chemotherapy for "high-risk" adult soft tissue sarcoma. Eur J Cancer 37: 1096-1103.
7. Issels RD, Abdel-Rahman S, Wendtner C, Falk MH, Kurze V, Sauer H et al (2001) Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer 37: 1599-1608.
8. Eggermont AM, Schraffordt Koops H, Liénard D, Kroon BB, van Geel AN, Hoekstra HJ et al (1996) Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14: 2653-2665.
9. Antman KH (1997) Adjuvant therapy of sarcomas of soft tissue. Semin Oncol 24: 556-560.
10. Lancet (1997) Adjuvant chemotherapy for localized resectable soft tissue sarcoma of adults: metaanalysis of individual data. Sarcoma Meta-analysis Collaboration 350: 1647-1654.
11. Frustaci S, Gherlinzoni F, De Paoli (2001) Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: result of Italian randomized cooperative trial. J Clin Oncol 19: 1238-1247.
12. Petrioli R, Coratti A, Correale P et al (2002) Adjuvant epirubicin with or without ifosfamide for adult soft tissue sarcoma. Am J Clin Oncol 25: 468-473.
13. Kattan MW, Leung DHY, Brennan MF (2002) Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 20: 791-796.
14. Spurrell EL, Fisher C, Thomas JM, Judson IR (2005) Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at Royal Marsden Hospital. Ann Oncol 16: 437-444.
15. Hensley ML, Maki R, Venkataraman E et al (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of phase II trial. J Clin Oncol 20: 2824-2831.
16. Hensley ML, Blessing JA, Mannel R, Rose PG (2008) Fixed dose rate gemcitabine plus docetaxel as first line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncologic group phase II study. Gynecol Oncol 109: 329-334.
17. Hensley ML, Blessing JA, Degeest K et al (2008) Fixed-dose rate gemcitabine plus docetaxel as second line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncologic group phase II study. Gynecol Oncol 109: 323-328.
18. Fata F, O'Reilly E, Ilson D et al (1999) Paclitaxel in treatment of patients with angiosarcomas of face or scalp. Cancer 86: 2034-2037.
19. Skubitz KM, Haddad PA (2005) Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 104: 361-366.
20. Eiling S, Lischner S, Busch JO, Rothaupt D, Christophers E, Hauschild A (2002) Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin. Br J Dermatol 147: 150-153.
21. Yovine A, Riofrio M, Blay JY et al (2004) Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcomas patients. J Clin Oncol 22: 890-899.
22. Garcia-Carbonero R, Supko JG, Manola J et al (2004) Phase II and pharmacokinetic study of ecteinascicin-743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22: 1480-1490.